Loomis Sayles & Company LP Has Raised Regeneron Pharmaceuticals (REGN) Position By $21.35 Million; Corrpro Companies (CO)’s Sentiment Is 2.27

February 22, 2018 - By Linda Rogers

China Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company has market cap of $1.21 billion. The firm offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. It has a 28.25 P/E ratio. As of March 31, 2017, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province.

Loomis Sayles & Company LP increased Regeneron Pharmaceuticals (REGN) stake by 2.62% reported in 2017Q3 SEC filing. Loomis Sayles & Company LP acquired 47,755 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Loomis Sayles & Company LP holds 1.87 million shares with $836.14M value, up from 1.82 million last quarter. Regeneron Pharmaceuticals now has $34.16B valuation. The stock increased 0.00% or $0.01 during the last trading session, reaching $317.52. About 483,890 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 22, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Since August 23, 2017, it had 0 insider purchases, and 5 selling transactions for $2.48 million activity. Shares for $330,574 were sold by Landry Robert E on Friday, September 1. Sanofi had bought 72,378 shares worth $34.84M. Shares for $900,000 were sold by BAKER CHARLES A. 1,500 shares were sold by BROWN MICHAEL S, worth $712,500. GOLDSTEIN JOSEPH L sold $325,600 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, February 9.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.21, from 1.38 in 2017Q2. It turned negative, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Advisors Asset Mgmt Inc has invested 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Ent Financial Service owns 0% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 19 shares. The United Kingdom-based Polar Limited Liability Partnership has invested 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Ubs Asset Management Americas owns 286,059 shares or 0.12% of their US portfolio. Massachusetts-based Massachusetts Svcs Ma has invested 0.1% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Shell Asset Management owns 15,435 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0.07% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Main Street Ltd Liability Corp has 0.05% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 725 shares. Next Century Growth Investors Limited Liability Corporation reported 1,697 shares. Fil accumulated 11,257 shares. Bbva Compass Bancshares Inc stated it has 0.4% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Tocqueville Asset LP has invested 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Banque Pictet & Cie accumulated 0.09% or 9,045 shares. Great West Life Assurance Can holds 0.07% or 66,536 shares. King Luther has invested 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Loomis Sayles & Company LP decreased Teledyne Technologies Inc (NYSE:TDY) stake by 7,452 shares to 101,584 valued at $16.17 million in 2017Q3. It also reduced Jp Morgan Chase & Co (NYSE:JPM) stake by 115,205 shares and now owns 1.36M shares. Sabra Health Care Reit Inc (NASDAQ:SBRA) was reduced too.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 19 Hold. Therefore 39% are positive. Regeneron Pharmaceuticals Inc. had 118 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Wednesday, June 14 with “Hold”. The firm earned “Buy” rating on Tuesday, March 15 by Gabelli. As per Monday, August 10, the company rating was maintained by TH Capital. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. On Tuesday, June 20 the stock rating was maintained by Piper Jaffray with “Buy”. Credit Suisse upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, August 3 to “Buy” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by UBS on Friday, August 4. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Outperform” rating by Raymond James on Tuesday, September 1. The firm has “Buy” rating by Argus Research given on Thursday, August 6. On Wednesday, August 5 the stock rating was maintained by Barclays Capital with “Equal Weight”.

The stock increased 0.57% or $0.06 during the last trading session, reaching $10.65. About 53,519 shares traded. China Cord Blood Corporation (CO) has risen 28.22% since February 22, 2017 and is uptrending. It has outperformed by 11.52% the S&P500.

Parametrica Management Ltd holds 1.43% of its portfolio in China Cord Blood Corporation for 304,903 shares. Lucus Advisors Llc owns 32,535 shares or 0.51% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.45% invested in the company for 880,000 shares. The United Kingdom-based Glg Partners Lp has invested 0.39% in the stock. Bogle Investment Management L P De, a Massachusetts-based fund reported 267,063 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts